PubRank

Mark R Cookson

Author PubWeight™ 206.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010 11.85
3 Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009 10.34
4 Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet 2010 8.74
5 Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006 5.96
6 The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A 2004 4.76
7 Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A 2005 4.22
8 Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006 3.60
9 DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008 3.03
10 DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet 2010 3.00
11 Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011 2.97
12 Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009 2.85
13 The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 2008 2.77
14 RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci U S A 2008 2.76
15 Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002 2.65
16 Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003 2.64
17 Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A 2008 2.64
18 Distinct DNA methylation changes highly correlated with chronological age in the human brain. Hum Mol Genet 2011 2.62
19 An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 2002 2.54
20 The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 2007 2.42
21 Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 2009 2.38
22 Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 2008 2.36
23 Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann Neurol 2008 2.34
24 Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One 2009 2.23
25 The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 2003 2.17
26 A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A 2011 2.15
27 L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem 2003 2.12
28 Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 2007 2.09
29 Evidence for natural antisense transcript-mediated inhibition of microRNA function. Genome Biol 2010 2.08
30 The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008 1.86
31 Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis 2006 1.83
32 Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. J Biol Chem 2009 1.71
33 Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J Neurochem 2007 1.70
34 Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease. FEBS J 2008 1.68
35 Evolutionary and functional relationships within the DJ1 superfamily. BMC Evol Biol 2004 1.67
36 The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites. Biochem Biophys Res Commun 2009 1.67
37 Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004 1.64
38 Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol 2006 1.60
39 MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies. Hum Mol Genet 2012 1.58
40 Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A 2014 1.53
41 Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 2002 1.43
42 Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am J Hum Genet 2010 1.42
43 The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 2010 1.39
44 Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis 2012 1.35
45 Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 2011 1.33
46 Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 2003 1.32
47 mRNA expression, splicing and editing in the embryonic and adult mouse cerebral cortex. Nat Neurosci 2013 1.29
48 Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A 2009 1.28
49 MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem 2010 1.28
50 Lysosomal impairment in Parkinson's disease. Mov Disord 2013 1.27
51 Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol 2009 1.27
52 Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res 2013 1.25
53 Reelin and stk25 have opposing roles in neuronal polarization and dendritic Golgi deployment. Cell 2010 1.25
54 Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 2003 1.22
55 LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS One 2011 1.19
56 DJ-1 regulation of mitochondrial function and autophagy through oxidative stress. Autophagy 2011 1.19
57 Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Brain Res Mol Brain Res 2005 1.18
58 Genes and parkinsonism. Lancet Neurol 2003 1.14
59 Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev Mol Med 2011 1.13
60 Amyotrophic lateral sclerosis 2-deficiency leads to neuronal degeneration in amyotrophic lateral sclerosis through altered AMPA receptor trafficking. J Neurosci 2006 1.13
61 The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Biochem J 2012 1.11
62 Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med 2012 1.10
63 Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One 2012 1.09
64 The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J Neurosci 2007 1.09
65 Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies. J Neurosci 2014 1.08
66 A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders. FASEB J 2004 1.07
67 Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays 2010 1.06
68 Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain. Proc Natl Acad Sci U S A 2014 1.05
69 The role of PTEN-induced kinase 1 in mitochondrial dysfunction and dynamics. Int J Biochem Cell Biol 2009 1.05
70 Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab 2011 1.02
71 Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet 2013 1.02
72 Age-associated miRNA alterations in skeletal muscle from rhesus monkeys reversed by caloric restriction. Aging (Albany NY) 2013 1.00
73 The R1441C mutation alters the folding properties of the ROC domain of LRRK2. Biochim Biophys Acta 2009 0.98
74 A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem 2013 0.97
75 Post-transcriptional regulation of mRNA associated with DJ-1 in sporadic Parkinson disease. Neurosci Lett 2009 0.96
76 Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue. PLoS One 2011 0.96
77 Cell population-specific expression analysis of human cerebellum. BMC Genomics 2012 0.95
78 Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics 2014 0.94
79 Variation in tau isoform expression in different brain regions and disease states. Neurobiol Aging 2013 0.94
80 Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J 2013 0.94
81 Differential gene expression in a cell culture model of SOD1-related familial motor neurone disease. Hum Mol Genet 2002 0.92
82 Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal 2011 0.92
83 Hexokinase activity is required for recruitment of parkin to depolarized mitochondria. Hum Mol Genet 2013 0.90
84 Genetic comorbidities in Parkinson's disease. Hum Mol Genet 2013 0.89
85 Expression of PINK1 mRNA in human and rodent brain and in Parkinson's disease. Brain Res 2007 0.88
86 Glial cell inclusions and the pathogenesis of neurodegenerative diseases. Neuron Glia Biol 2004 0.88
87 Age-associated changes in gene expression in human brain and isolated neurons. Neurobiol Aging 2012 0.87
88 Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson's disease. J Neurochem 2005 0.87
89 Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci 2010 0.85
90 Normal localization of deltaF323-Y328 mutant torsinA in transfected human cells. Neurosci Lett 2002 0.85
91 Selective loss of neurofilament expression in Cu/Zn superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J Neurochem 2002 0.85
92 Gene expression in the Parkinson's disease brain. Brain Res Bull 2011 0.85
93 Animal models for drug discovery in dystonia. Expert Opin Drug Discov 2008 0.84
94 14-3-3 proteins are promising LRRK2 interactors. Biochem J 2010 0.83
95 Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease. Neuroscientist 2004 0.80
96 Parkinson disease, cancer, and LRRK2: causation or association? Neurology 2012 0.80
97 Identification of Stk25 as a genetic modifier of Tau phosphorylation in Dab1-mutant mice. PLoS One 2012 0.80
98 Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J 2009 0.80
99 Sequence conservation between mouse and human synphilin-1. Neurosci Lett 2002 0.79
100 Deep sequencing of coding and non-coding RNA in the CNS. Brain Res 2010 0.79
101 Development, characterisation and epitope mapping of novel monoclonal antibodies for DJ-1 (PARK7) protein. Neurosci Lett 2005 0.79
102 Use of cysteine-reactive cross-linkers to probe conformational flexibility of human DJ-1 demonstrates that Glu18 mutations are dimers. J Neurochem 2014 0.79
103 Biochemical characterization of torsinB. Brain Res Mol Brain Res 2004 0.79
104 Parkin-mediated ubiquitination regulates phospholipase C-gamma1. J Cell Mol Med 2008 0.79
105 Microarray analysis reveals induction of heat shock proteins mRNAs by the torsion dystonia protein, TorsinA. Neurosci Lett 2003 0.78
106 Identification of the epitope of a monoclonal antibody to DJ-1. Neurosci Lett 2004 0.77
107 Astrocytes in Parkinson's disease and DJ-1. J Neurochem 2011 0.77
108 LRRK2: dropping (kinase) inhibitions and seeking an (immune) response. J Neurochem 2014 0.76
109 Roles of the proteasome in neurodegenerative disease: refining the hypothesis. Ann Neurol 2004 0.75
110 Age-modulated association between prefrontal NAA and the BDNF gene. Int J Neuropsychopharmacol 2012 0.75
111 Neurons inflict self-harm. Nat Med 2005 0.75
112 Editorial hot topic: drug targets in Parkinson's disease: where are we and where should we go?]. CNS Neurol Disord Drug Targets 2011 0.75
113 Dominant torsinA mutations in cellular systems. Adv Neurol 2004 0.75
114 Unaltered alpha-synuclein blood levels in juvenile Parkinsonism with a parkin exon 4 deletion. Neurosci Lett 2004 0.75